Positive
●
Proactive Investors
●
4 months ago
Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma. Under the terms of the definitive agreement announced Sunday, AbbVie will acquire all outstanding Apogee shares ...